Trinicalm Plus
✅ Manages psychiatric symptoms
✅ Controls involuntary movements
✅ Reduces anxiety
✅ Improves motor function
✅ Enhances quality of life
Trinicalm Plus contains Trifluoperazine and Trihexyphenidyl.
✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026
⚡ Quick Answer — What is Trinicalm Plus?
Trinicalm Plus contains a fixed-dose combination of trifluoperazine 5 mg + trihexyphenidyl 2 mg from a WHO-GMP certified manufacturer (Tripada Healthcare) — a first-generation antipsychotic (D2 antagonist) paired with an anticholinergic anti-Parkinson agent to pre-empt the extrapyramidal side effects (EPS — parkinsonism, dystonia, akathisia) that high-potency typical antipsychotics commonly cause. Used primarily in countries where typical antipsychotics remain in regular use for schizophrenia and severe anxiety/agitation. Important warnings: trifluoperazine carries the FDA black box for elderly dementia mortality, plus high tardive dyskinesia and neuroleptic malignant syndrome risks; trihexyphenidyl has anticholinergic side effects (cognitive impairment, urinary retention, falls in elderly) and recognised abuse potential (sought for its euphoric / stimulant effect at supratherapeutic doses).
📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.
Why order from MedsBase
Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging — no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor — never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.
What Is Trinicalm Plus?
Trinicalm Plus is an oral tablet of trifluoperazine 5 mg + trihexyphenidyl 2 mg in fixed-dose combination, manufactured by Tripada Healthcare. The combination addresses a long-standing problem with first-generation antipsychotics: high-potency D2 antagonists like trifluoperazine routinely cause extrapyramidal side effects (drug-induced parkinsonism, akathisia, acute dystonia) that limit tolerability and adherence. Co-prescribing an anticholinergic anti-Parkinson agent like trihexyphenidyl mitigates these motor side effects.
This is a second-line approach in modern psychiatry — first-line is to use an atypical antipsychotic (which has lower EPS risk and does not require routine anticholinergic cover). The combination remains common in countries where typical antipsychotics are first-line for cost or availability reasons.
Component Drugs
What each component does
| Component | Class | Mechanism | Role in this combination |
|---|---|---|---|
| Trifluoperazine 5 mg | First-generation phenothiazine antipsychotic (high-potency) | Tight D2 antagonism in mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular pathways | Primary antipsychotic action; also approved for short-term treatment of severe non-psychotic anxiety not responsive to usual measures (legacy indication) |
| Trihexyphenidyl 2 mg | Centrally-acting anticholinergic anti-Parkinson agent | M1 muscarinic antagonism in the basal ganglia, restoring acetylcholine / dopamine balance | Pre-empts and treats trifluoperazine-induced parkinsonism, dystonia, and akathisia |
Approved Indications
- Schizophrenia and other psychotic disorders requiring trifluoperazine therapy with prophylactic EPS coverage
- Severe anxiety / agitation not responsive to standard treatment (legacy trifluoperazine indication; first-line modern alternatives are SSRIs and atypical antipsychotics)
Dosing
| Indication | Typical dose | Maximum | Notes |
|---|---|---|---|
| Schizophrenia / psychosis | 1 tablet (5/2) BID–TID | 3 tablets (15 mg trifluoperazine + 6 mg trihexyphenidyl) per day | Trifluoperazine total 5–15 mg/day in fixed combination; higher trifluoperazine doses require separate dosing |
| Severe anxiety | 1 tablet BID | 2 tablets/day | Short-term only — weeks rather than months; reassess for switch to SSRI / SNRI |
| Elderly | ½ tablet BID if combination is unavoidable | — | High EPS, anticholinergic, and falls risk; black-box dementia warning |
Side Effects (by Component)
Trifluoperazine side effects
| Mechanism | Effects | Notes |
|---|---|---|
| D2 blockade (nigrostriatal) | Acute dystonia (eye-rolling, torticollis, jaw clenching), parkinsonism (tremor, rigidity, bradykinesia), akathisia (inner restlessness), tardive dyskinesia (long-term involuntary movements) | High risk — the reason trihexyphenidyl is co-prescribed; tardive dyskinesia can be irreversible and develops with long-term exposure |
| D2 blockade (tuberoinfundibular) | Hyperprolactinaemia (galactorrhoea, gynaecomastia, amenorrhoea, sexual dysfunction) | Common with high-potency typicals |
| H1 blockade | Sedation | Less than chlorpromazine |
| Alpha-1 blockade | Orthostatic hypotension | Less than chlorpromazine |
| QT prolongation | Cardiac arrhythmia risk | Baseline ECG; caution with other QT-prolonging drugs |
| Other | Photosensitivity, ocular changes, jaundice | Long-term concerns |
| Rare but serious | Neuroleptic malignant syndrome (hyperthermia, rigidity, autonomic instability, altered mental status) | Medical emergency |
| Rare | Lowered seizure threshold | Caution in epilepsy |
Trihexyphenidyl side effects
| Mechanism | Effects | Notes |
|---|---|---|
| Peripheral anticholinergic | Dry mouth, blurred vision, constipation, urinary retention | Common; particularly problematic with BPH |
| Central anticholinergic | Confusion, memory impairment, cognitive dulling, agitation | Older adults at greatest risk — linked to long-term cognitive decline |
| Other | Tachycardia, dizziness, falls | Falls risk in elderly |
| Important | Abuse potential | Trihexyphenidyl is sought at supratherapeutic doses for euphoric / stimulant / hallucinogenic effects; some jurisdictions have introduced controls. Patients with substance use history need monitoring |
Drug Interactions
QT prolongation: avoid combination with other QT-prolonging drugs — ziprasidone, citalopram (high dose), methadone, ondansetron, fluoroquinolones.
Anticholinergic stacking: trihexyphenidyl already pushes anticholinergic burden — combine cautiously with TCAs, paroxetine, antihistamines, oxybutynin, hyoscyamine; in older adults this can produce confusion, falls, and urinary retention.
CNS depression: alcohol, benzodiazepines, opioids — additive sedation.
Antihypertensives: additive orthostasis.
Levodopa antagonism: trifluoperazine D2 blockade reduces levodopa effect — problematic in Parkinson’s disease.
Why Modern Practice Often Avoids This Combination
Where atypical antipsychotics are available and affordable, modern practice generally avoids first-generation antipsychotics + routine anticholinergic cover because:
- Tardive dyskinesia risk is much higher with first-generation antipsychotics — cumulative, often irreversible
- Anticholinergic cognitive burden is now linked to long-term cognitive decline and dementia risk in older adults
- Trihexyphenidyl abuse potential is recognised — some jurisdictions have introduced scheduling
- Atypicals (risperidone, quetiapine, aripiprazole, ziprasidone) have lower EPS risk and rarely require routine anticholinergic cover
This combination remains in use where typical antipsychotics are first-line by cost or availability, in legacy patient regimens, and for patients who are stable and tolerating it well after years of treatment.
Frequently Asked Questions
Why is trihexyphenidyl combined with trifluoperazine?
High-potency first-generation antipsychotics like trifluoperazine routinely cause drug-induced parkinsonism, dystonia, and akathisia from D2 blockade in the basal ganglia. Trihexyphenidyl is an anticholinergic anti-Parkinson agent that restores acetylcholine / dopamine balance and pre-empts these motor side effects.
Is Trinicalm Plus still a good choice in 2026?
Modern practice generally favours atypical antipsychotics (risperidone, quetiapine, aripiprazole, ziprasidone) where available — lower EPS risk, no routine anticholinergic cover needed. The trifluoperazine + trihexyphenidyl combination remains common where typical antipsychotics are first-line and in stable legacy regimens.
What is tardive dyskinesia and why does it matter?
Tardive dyskinesia is a movement disorder — involuntary, repetitive movements of the face, mouth, tongue, or limbs — that can develop after months to years of dopamine-blocking antipsychotic treatment. It is more common with first-generation antipsychotics and can be irreversible even after stopping the drug. Annual screening (Abnormal Involuntary Movement Scale) is standard.
Will Trinicalm Plus cause weight gain?
Less than atypical antipsychotics like olanzapine or clozapine. Trifluoperazine has only modest metabolic effect.
Is trihexyphenidyl addictive?
Trihexyphenidyl is sought at supratherapeutic doses for euphoric and stimulant effects in some communities and is recognised to have abuse potential. Some jurisdictions have introduced prescription controls. Patients with substance use history need monitoring; lock storage is sensible if children or vulnerable adults are in the home.
Can I drink alcohol on Trinicalm Plus?
Avoid — additive sedation, orthostasis, and falls risk. Alcohol also worsens the cognitive effects of trihexyphenidyl.
Is Trinicalm Plus safe in elderly patients?
Anticholinergic burden, sedation, orthostasis, and falls risk make this combination poorly tolerated in elderly. Black-box dementia warning applies (trifluoperazine). Atypical antipsychotic monotherapy is usually a better fit when antipsychotic treatment is needed.
Can I stop Trinicalm Plus abruptly?
Better to taper. Abrupt stopping can produce withdrawal dyskinesia (uncovers latent tardive movements), insomnia, agitation, and rebound psychosis. Anticholinergic withdrawal can produce cholinergic rebound (sweating, GI upset, restlessness). Reduce gradually under prescriber supervision.
How is Trinicalm Plus different from risperidone or quetiapine?
Atypicals (risperidone, quetiapine, aripiprazole, ziprasidone) bind D2 receptors more loosely and add 5-HT2A antagonism — lower EPS risk, no routine anticholinergic cover needed, lower tardive dyskinesia risk. Trade-off: more metabolic side effects with some atypicals (olanzapine, quetiapine).
How should Trinicalm Plus be stored?
Store at 15–30 °C in the original blister packaging away from moisture and sunlight. Lock-store if children or vulnerable adults are in the home — both components, particularly trihexyphenidyl, can be sought for misuse.
Related Alternatives
Other products in Chronic Conditions that customers also view:
More options in Situational Anxiety Treatment
Ranked by recent MedsBase order volume — what other customers in this category are picking.
| Strength | 5mg+2mg |
|---|---|
| Quantity | 30 Tablet/s, 60 Tablet/s, 90 Tablet/s, 180 Tablet/s |
Trinicalm Plus
Q & A
Trinicalm Plus
Related products
Reviews
There are no reviews yet